Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Agenus Inc (AGEN)

Agenus Inc (AGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 803,480
  • Shares Outstanding, K 183,443
  • Annual Sales, $ 150,050 K
  • Annual Income, $ -107,660 K
  • 60-Month Beta 1.98
  • Price/Sales 5.22
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AGEN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.26
  • Number of Estimates 3
  • High Estimate -0.24
  • Low Estimate -0.27
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +21.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.88 +8.25%
on 10/05/20
5.16 -18.68%
on 09/21/20
-0.98 (-18.92%)
since 09/18/20
3-Month
2.89 +45.32%
on 07/30/20
5.63 -25.40%
on 09/11/20
+0.60 (+16.67%)
since 07/17/20
52-Week
1.82 +130.77%
on 03/23/20
5.63 -25.40%
on 09/11/20
+1.58 (+60.31%)
since 10/18/19

Most Recent Stories

More News
Agenus to Present on Seven Novel Programs at SITC 2020

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections,...

AGEN : 4.20 (-4.11%)
Susan Hirsch Joins Agenus' Board of Directors

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections,...

AGEN : 4.20 (-4.11%)
Agenus Inc Up 39.6% Since SmarTrend Uptrend Call (AGEN)

SmarTrend identified an Uptrend for Agenus Inc (NASDAQ:AGEN) on August 10th, 2020 at $3.71. In approximately 1 month, Agenus Inc has returned 39.62% as of today's recent price of $5.18.

AGEN : 4.20 (-4.11%)
Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab

Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.

AGEN : 4.20 (-4.11%)
EBS : 95.97 (-2.94%)
ALIM : 4.61 (-1.28%)
TECH : 264.58 (-0.41%)
SmarTrend Watching for Potential Rebound in Shares of Agenus Inc After 1.54% Loss

Agenus Inc (NASDAQ:AGEN) traded in a range yesterday that spanned from a low of $4.85 to a high of $5.45. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $4.97 on...

AGEN : 4.20 (-4.11%)
Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections,...

AGEN : 4.20 (-4.11%)
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO

-- 160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients

AGEN : 4.20 (-4.11%)
Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections,...

AGEN : 4.20 (-4.11%)
Agenus to Participate in Webcast Hosted by William Blair on ESMO2020 Results and Novel Pipeline

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections,...

AGEN : 4.20 (-4.11%)
Agenus Inc Up 39.9% Since SmarTrend Uptrend Call (AGEN)

SmarTrend identified an Uptrend for Agenus Inc (NASDAQ:AGEN) on August 10th, 2020 at $3.71. In approximately 1 month, Agenus Inc has returned 39.89% as of today's recent price of $5.19.

AGEN : 4.20 (-4.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

2nd Resistance Point 4.55
1st Resistance Point 4.38
Last Price 4.20
1st Support Level 4.10
2nd Support Level 3.99

See More

52-Week High 5.63
Last Price 4.20
Fibonacci 61.8% 4.17
Fibonacci 50% 3.73
Fibonacci 38.2% 3.28
52-Week Low 1.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar